



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Dimitra Georganopoulou

Tel: (847) 491-8513

Fax: (847) 491-8510

dimitra@ohmx.com

Ohmx adds to its growing publication list

Evanston IL, October 26th 2010 – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for monitoring of chronic diseases, is pleased to announce the acceptance of a scientific paper to Dalton Transactions, a member of RSC Publishing. This publication is the latest in a growing list of peer-reviewed publications and white papers available from the company, including:

Spectroscopic and Redox Properties of Amine-Functionalized $K_2[Os^{II}(bpy)(CN)_4]$ Complexes. M. J. Ahrens, P. A. Bertin, A. G. Gaustad, D. Georganopoulou, M. Wunder, G. F. Blackburn, H. B. Gray, & T. J. Meade. **2011, Accepted, DOI: 10.1039/c0dt01478h**

Ferrocene and maleimide-functionalized disulfide scaffolds for self-assembled Monolayers on gold. P. A. Bertin, M. J. Ahrens, K. Bhavsar, D. Georganopoulou, M. Wunder, G. F. Blackburn, T. J. Meade, *Organic Letters* **2010**, 12, 3372.

Novel redox active bifunctional crosslinkers from unsymmetrical 1,1'-disubstituted ferrocenes. P. A. Bertin, T. J. Meade, *Tetrahedron Letters* **2009**, 50, 5409.

Protein binding and the electronic properties of iron(II) complexes: An electrochemical and optical investigation of outer sphere effects. K. D. Barker, A. L. Eckermann, M. H. Sazinsky, M. R. Hartings, C. Abajian, D. Georganopoulou, M. A. Ratner, A. C. Rosenzweig, T. J. Meade, *Bioconjugate Chemistry* **2009**, 20, 1930.

Electroactive self-assembled monolayers on gold via bipodal dithiazepane anchoring groups. P. A. Bertin, D. Georganopoulou, T. Y. Liang, A. L. Eckermann, M. Wunder, M. J. Ahrens, G. F. Blackburn, T. J. Meade, *Langmuir* **2008**, 24, 9096.

About the Company:

Ohmx is advancing e-Diagnostics by developing a home monitoring device that can quantify clinical biomarkers and other important disease indicators from a finger prick. Ohmx's handheld monitoring device is electronic, low-cost, user-friendly, contains advanced communications protocols and can be used as a near-patient analyzer in the convenience of the patient's home. Except for diabetes, there are few consumer devices that can monitor chronic diseases. Ohmx systems address this unmet need by offering a comprehensive platform for tests routinely used for chronic disease monitoring, including cardiac markers, blood gases, electrolytes, metabolites, lipids, cholesterol, glucose, glycosylated serum proteins and hemoglobin. Ohmx was founded by NU Prof. Thomas Meade, PhD, who sold his prior company to Motorola for \$300MM; President & CEO is

Barbara Dyson and R&D is headed by Dimitra Georganopoulou, PhD (Inverness, Nanosphere). Ohmx seeks to raise \$8.3MM to fund manufacturing, product launch and commercialization. The Company has raised \$11.1MM to date.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.